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Identification of small molecule 
inhibitors of Interleukin-18
Brian Krumm1,3, Xiangzhi Meng2, Yan Xiang2 & Junpeng Deng1
Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory cytokine belonging to the IL-1 superfamily. 
IL-18 plays an important role in host innate and adaptive immune defense but its aberrant activities 
are also associated with inflammatory diseases such as rheumatoid arthritis and Crohn's disease. IL-18 
activity is modulated in vivo by its naturally occurring antagonist, IL-18 Binding Protein (IL-18BP). 
Recent crystal structures of human IL-18 (hIL-18) in complex with its antagonists or cognate receptor(s) 
have revealed a conserved binding interface on hIL-18. Through virtual screening of the National 
Cancer Institute Diversity Set II and in vitro competitive ELISA we have identified three compounds 
(NSC201631, NSC80734, and NSC61610) that disrupt hIL-18 binding to the ectromelia virus IL-18BP. 
Through cell-based bioassay, we show that NSC80734 inhibits IL-18-induced production of IFN-γ 
in a dose-dependent manner with an EC50 of ~250 nM. Our results and methodology presented here 
demonstrate the feasibility of developing small molecule inhibitors that specifically target the rather 
large interface of IL-18 that is involved in extensive protein-protein interactions with both IL-18BP and 
its cognate receptor(s). Our data therefore provide the basis for an approach by which small molecules 
can be identified that modulate IL-18 activity.
Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory cytokine belonging to the IL-1 superfamily1–3. IL-18 
plays an important regulatory role in both innate and acquired immune responses against pathogenic infec-
tions. IL-18 was originally referred to as IFN-γ Inducing Factor (IGIF) for its ability to stimulate the production 
of IFN-γ3, 4. IL-18 stimulates IFN-γ production from T-helper lymphocytes cells (Th1) and macrophages, and 
enhances the cytotoxicity of natural killer (NK) cells. The IL-18 stimulated IFN-γ production is synergistically 
amplified with other Th1-related cytokines, IL-2, IL-15, IL-12 and IL-235–8. IL-18 is synthesized as a 23 kDa inac-
tive precursor, which is subsequently cleaved into an 18 kDa active form by a member of the inflammasome 
(Interleukin-1β Converting Enzyme, ICE (Caspase-1)) and then secreted, resulting in the initiation of IL-18 
signaling cascade3, 9. IL-18 signals through its two membrane bound receptors, IL-18Rα and IL-18Rβ, form-
ing a ternary complex necessary for productive intracellular signaling10. IL-18 activity is modulated in vivo by 
Interleukin-18 Binding Protein (IL-18BP), a soluble protein comprised of a single Immunoglobulin (Ig) domain11, 
12. The human IL-18BP (hIL-18BP) has an exceptionally high affinity for hIL-18 of 400 pM and has been shown 
to be up-regulated in various cell lines in response to elevated IFN-γ levels, suggesting that it serves as a negative 
feedback inhibitor of hIL-18 mediated immune response12, 13.
Despite its significant role in host immune response against infection, aberrant hIL-18 bioactivity has been 
associated with inflammatory and autoimmune diseases, allergies, and neurological disorders8, 14, 15. In fact, it 
has been shown that increased levels of mature hIL-18 have a direct correlation with the severity of pathological 
autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), and lupus16. Therefore, down 
regulating hIL-18 bioactivity seems to be a logical approach for treatment of inflammatory and autoimmune dis-
eases. A current strategy for treating these human diseases is to target proteins involved in the initiation event(s) 
of inflammation or upstream events of the innate immune response. These upstream effector proteins include but 
are not limited to Cyclooxygenase-2 (Cox-2) and Caspase-1, which respond to Non-Steroidal Anti-Inflammatory 
Drugs (NSAID) or specific caspase inhibitors, respectively. However these treatments suffer from side effects such 
as colitis17.
There exist potential therapies that involve the use of antibodies directed against the interface of hIL-18 and 
hIL-18Rα or the use of recombinant hIL-18BP, both of which are being tested in clinical trials18, 19. Recombinant 
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hIL-18BP has been shown to be effective at treating inflammatory skin diseases and LPS-induced liver injury20, 21. 
The use of hIL-18BP to treat these pathological conditions has met with some success in clinical trials but has 
also met with complications often causing immunogenic reaction themselves16. Therefore, protein-based immu-
notherapy strategies face potential drawbacks such as immunogenic rejections, and other such complications 
especially with immune compromised individuals16, 22, 23. Developing small molecule inhibitors presents a novel 
approach for down regulating hIL-18 bioactivity in part due to their bioavailability and might also serve as better 
alternatives.
Functional IL-18BPs, natural IL-18 inhibitors, are not limited to just vertebrates but are also encoded by 
many poxviruses including Molluscum Contagiosum Virus (MCV) and orthopoxviruses. It has been shown that 
IL-18BP from poxviruses species of ectromelia and vaccinia virus contributes to virulence by down-modulating 
IL-18 mediated immune responses, suggesting a possible role as a decoy for human immune evasion24, 25. The 
molecular mechanism by which IL-18BP modulates hIL-18 signaling has been elucidated from two recent 
high-resolution crystal structures of hIL-18 in complex with two divergent IL-18BPs from ectromelia (ectv26), 
and yaba-like disease virus (yldv27). It was shown that both IL-18BPs bind to the same surface of hIL-18 used 
by other IL-18BPs, suggesting that all IL-18BPs, including hIL-18BP, use a conserved inhibitory mechanism by 
blocking a conserved surface on hIL-18 that is commonly shared for binding hIL-18Rα (Fig. 1). The crystal struc-
tures of hIL-18 in complex with viral IL-18BPs revealed that the interface on hIL-18 is hydrophobic in nature 
with as much as 1,930 Å2 buried surface area26 comprised of three distinct sites A, B, and C. This interface is also 
shared by hIL-18Rα D3 domain for signaling10. Contained within hIL-18 binding site A is a critical hIL-18 Lysine 
residue (K53) when mutated to alanine displayed a greater than 100- and 4-fold decrease in binding affinity for 
variola IL-18BP and hIL-18Rα, respectively28. In fact, K53A mutation of hIL18 increased IL-18 bioactivities due 
to its reduced ability of being inhibited by IL-18BP, indicating that binding site A on hIL-18 surface is a ‘hot spot’. 
Additionally, hIL-18 binding site C is also another potential ‘hot spot’ as it pockets a highly conserved orthopox-
virus Phenlyalanine that has been shown to be critical for orthopoxvirus, molluscum contagiosum virus (MCV), 
and human IL-18BP complex formation27, 29–31. Alanine substitutions of residues that surround binding site C, 
(G108, H109, and K112) abrogated hIL-18 ternary complex formation10. The identified surface patches on hIL-18 
could therefore be targeted toward designing small molecule compounds as rational inhibitors against hIL-18 
activity.
Protein-protein interactions are associated with most crucial biological processes including signal transduc-
tion, cell adhesion, cellular proliferation, growth and differentiation to name a few while their malfunctions have 
been identified in numerous pathological disease states32. It is estimated that up to 650,000 interactions reg-
ulate biological processes within the human cell with these protein-protein interactions having been termed 
the ‘interactome’33. While most small molecule drugs currently on the market are either competitive inhibi-
tors of G-protein-coupled receptors, nuclear receptors, ion channels or an enzymatic target, there exist a small 
but increasing number of protein-protein inhibitors (PPIs) showing a degree of success in clinical trials34–36. 
Protein-protein inhibitor discovery focuses on targeting binding clefts and ‘hot spots’ at protein interfaces for 
which small molecules or fragments can modulate their activity. However, this is not always effective noting that 
protein-protein interfaces are very large ranging from 1,300–3,000 Å2 in buried surface area and tend to be on 
average hydrophobic in nature37, 38. To date, small molecule inhibitors of IL-2 exemplify rational drug design 
Figure 1. Human IL-18 Viral and Ternary Receptor Complex Crystal Structures. (A) Crystal structure of 
hIL-18:ectvIL-18BP viral complex, PDB entry 3F62. Depicted in ribbon diagram and colored in light yellow 
is ectvIL-18BP, hIL-18 is drawn in surface representation. Residues of ectvIL-18BP at the interface are shown 
as sticks, interacting with previously identified binding sites on hIL-18 colored as site A (red), site B (orange), 
and site C (cyan). The remaining surface of hIL-18 is colored in grey. (B) Crystal structure of hIL-18 ternary 
receptor complex, PDB entry 3WO4. Drawn as cartoon representation and colored green and magenta are hIL-
18 Receptor α and β, respectively. Human IL-18 has been drawn as seen in panel A.
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targeting cytokines. IL-2 is a cytokine with a four-helix bundle structure. A panel of small molecules that binds to 
IL-2 directly were developed at Sunesis Pharmaceuticals with the tightest binding molecule having a disassocia-
tion constant in the mid-nanomolar range. These small molecules bind directly on IL-2 and disrupt the interac-
tion between IL-2 and the a-chain of the IL-2 receptor39–41.
To date, there are no published data for small molecules specifically targeting hIL-18 or its receptor complex. 
The identification of small molecules targeting hIL-18 could potentially open up new avenues for the discovery 
of novel therapeutics for the treatment of pathological diseases associated with hIL-18 bioactivity. Based on the 
structural data from hIL-18 and viral IL-18BPs complexes, we used Autodock42 to perform in silico screening 
of small molecule compounds representative of the National Cancer Institute (NCI) depository. The inhibitory 
effects of potential small molecule leads identified from in silico screening were confirmed by an in vitro compet-
itive ELISA assay between hIL-18 and ectvIL-18BP. We also show in a cell-based assay that the identified small 
molecule inhibitors blocked hIL-18 stimulated IFN-γ production.
Results
Using the Autodock program43, 44 we performed virtual screening for small molecules that could potentially fit into 
the identified IL-18 binding interface pockets. Approximately 1,500 compounds from the NCI Diversity Set II ligand 
library representing greater than 250,000 compounds in the NCI repository were used to identify potential inhibi-
tors. We designed a grid box incorporating the hIL-18 surface (including site A, B, and C) for docking of compounds 
and searched for the lowest possible binding energy of potential inhibitors. Autodock returned predicted binding 
poses grouped in binding clusters with a root mean square deviation (r.m.s.d.) tolerance of less than 1 Å between 
poses of the cluster. The results were evaluated by ranking various complexes toward the predicted binding energy. 
Cluster analysis was subsequently accomplished on the basis of r.m.s.d. values with respect to the starting ligand 
geometry. The docked conformation with the most favorable binding free energy and the more populated cluster 
was selected as the best result. For each cluster, the estimated free energy of binding in kcal mol−1 was obtained and 
an estimated inhibition constant (Ki) at 298.15 K was derived. Virtual screening of the NCI Diversity Set II identified 
twenty-seven unique compounds with a predicted Ki of less than 1 uM, which were subsequently obtained from the 
NCI Developmental Therapeutics Program (NCI/DTP, http://dtp.nci.nih.gov).
We assessed the ability of the twenty-seven compounds for inhibiting the binding between hIL-18 and 
ectvIL-18BP by using a competitive ELISA method. Since the interface of hIL-18:IL-18BP is shared by IL-18Rα, 
ectvIL-18BP is used in the ELISA assays as an easy readout for screening inhibitors of IL-18 signaling. Specifically, 
we added biotinylated hIL-18 together with varying concentrations of the compound to the wells coated with 
purified MBP-ectvIL-18BP. We detected the amount of bound hIL-18 using a streptavidin-HRP conjugate in 
the presence of 5% (v/v) DMSO alone and a proven non-inhibitory compound were used as negative controls. 
Three compounds, NSC201631 (ethyl 4-[[4-amino-3-cyano-5-(3-nitrobenzoyl)thiophen-2-yl]amino]benzo-
ate), NSC80734 (1-(4-cyanophenyl)-3-[4-[4-[(4-cyanophenyl)carbamoylamino]phenoxy]phenyl]urea), and 
NSC61610 (1-N,4-N-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide) inhibited binding in a 
dose-dependent manner with IC50 of 44+/− 9 uM (n = 3), 52+/− 38 uM (n = 3) and 6+/− 5 uM (n = 2), with 
calculated Ki of 1.6 uM, 1.8 uM, and 0.2 uM, respectively (Fig. 2).
In virtual screening, compound NSC201631 had a predicted Ki of 903 nM and docked into the induced fit cav-
ities of binding sites A and B with a majority of the molecule residing in binding site A (Fig. 3A); NSC80734 had a 
predicted Ki of 409 nM and docked with half of the molecule laying off to the side of hIL-18 between β strands β5 
and β8, the other half of the molecule docked on to the side of binding site C (Fig. 3B); NSC61610 had a predicted 
Ki of 88 nM and docked across the β-trefoil opening extending from one side of β-trefoil opening to the other 
and was anchored similar to NSC80734 with one end of the molecule inserted between β strands β5 and β8 and 
the other end interacting with the C-terminus β12 while occupying a significantly greater area of binding site C 
when compared to NSC80734 (Fig. 3C). The calculated Ki values derived from the competitive ELISA data were 
approximately 2-fold lower for NSC201631 and NSC61610 while approximately 4-fold lower for NSC80734 than 
the predicted Autodock Ki values. Thus, the ranking order of these compounds based on the Ki values was dif-
ferent for Autodock and the competitive ELISA but NSC61610 still had the highest inhibition constant for both.
As the three identified compounds docked in different surface pockets on hIL-18 and compounds NSC80734 
and NSC61610 docked in different poses in binding site C, we wanted to determine if there exist any synergistic or 
additive effects between these three compounds. Combining NSC201631 and NSC80734 had the most significant 
additive effect with an approximate 5- to 6-fold increase in IC50 in the competitive ELISA with an IC50 of 9.3 uM 
(n = 1) (Fig. 2B) when comparing the individual compounds suggesting they occupy two non-overlapping sites 
on hIL-18 and consistent with the predicted docking pose(s). Combining NSC201631 and NSC61610 had a mod-
est additive effect with a slight increase in IC50 of 3.7 uM (n = 1) (Fig. 2C) when compared to NSC61610 alone but 
also consistent with occupying two non-overlapping binding sites. Human IL-18 induces IFN-γ production in 
human KG-1 cells. We used this bioassay and tested the three compounds for their ability to inhibit hIL-18 activ-
ities. Interestingly, NSC201631 did not inhibit hIL-18 activities, while NSC61610 had a small inhibitory effect on 
hIL-18 activities. Compound NSC80734 displayed the best inhibition of hIL-18 induced stimulation of IFN-γ in 
a dose-dependent manner with an EC50 of ~250 nM (Figs 4 and 5).
Discussion
Protein-protein inhibitor discovery focuses on targeting binding clefts and ‘hot spots’ at protein interfaces for 
which small molecules or fragments can modulate their activity. However, this is not always effective noting that 
protein-protein interfaces are very large ranging from 1,300–3,000 Å2 in buried surface area and tend to be on 
average hydrophobic in nature37, 38.
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The crystal structures of hIL-18 in complex with viral IL-18BPs revealed that the interface is hydrophobic 
in nature with as much as 1,930 Å2 buried surface area26. This interface is comprised of three distinct sites A, B, 
and C, which are also shared by hIL-18Rα D3 domain for signaling. Human IL-18 binding site A and B cavities 
were occupied by ectvIL-18BP residues Y51, Y53, and F67 in the complex structure, these residues are highly 
conserved in poxvirus species and play critical roles (Y53 and F67) in binding hIL-1828–31. Mutations to residues 
surrounding hIL-18 binding site C completely eliminated ternary complex formation10. Human IL-18 surface 
sites A, B, and C are thus appropriately sized for small-molecule binding.
Our docking and competitive ELISA data suggest that compounds NSC201631 and NSC61610 would bind 
to the surface of hIL-18 and thus prevent viral and human IL-18BPs complex formation. Interestingly, although 
compound NSC80734 showed less binding to hIL-18 when compared to NSC61610 (Fig. 2B and C) in our 
competitive ELISA experiment, it displayed the best inhibition on IL-18 signaling in our cell-based bioassay 
(Fig. 4A and B). It is speculative that NSC80734, upon binding to site C on IL18, could disrupt the recruitment 
of hIL-18Rβ into the signaling receptor ternary complex preventing downstream hIL-18 mediated signaling. 
The data also suggest the surface on IL-18, although shared between IL-18BP and IL-18 receptors, may have 
varying energetic contributions to the binding of either protein. Thus the discovery of these three compounds 
(NSC201631, NSC80734, and NSC61610) through virtual screening, competitive ELISA, and bioassay serves as 
a proof-of-principle. The data provides a unique opportunity for structure based drug design to develop more 
potent inhibitors that could discriminate between hIL-18BP and hIL-18 ternary receptor complex formation for 
the treatment of not only diseases attributed to orthopoxvirus infections but also to pathogenic human diseases 
attributed to the aberrant expression of hIL-18. Further detailed structure-activity studies on these inhibitors will 
be needed for development of compounds with tighter binding affinities, improved efficacy and perhaps toxicity. 
All of which should benefit and be guided by high-resolution structures and medicinal chemistry.
Experimental Procedures
Virtual Screening. In silico docking of hIL-18 with potential inhibitors was carried out using the Autodock 
program (version 4.2) from the Molecular Graphic Laboratory of the Scripps Research Institute43, 45. AutoDock 
uses a genetic algorithm to generate the poses of the ligand inside a known or predicted binding site utilizing the 
Figure 2. Competitive ELISA and IC50 determination. Dose-response curves with varying compound 
concentrations for the inhibition of hIL-18:ectvIL-18BP complex formation. IC50 values were obtained by 
nonlinear regression fitting to a variable slope, three-parameter dose-response model using the GraphPad 
Prism 6 software (San Diego, CA, USA). Competitive ELISA experiments were performed using four technical 
replicates. (A) Competitive ELISA curve for NSC201631, IC50 = 44+/− 9 uM, n = 3. (B) Competitive and 
Synergistic ELISA results for NSC80734, IC50 = 52 + / 38 uM, n = 3 and NSC201631/80734 (IC50 = 9.3 uM). (C) 
Competitive and Synergistic ELISA results for NSC61610, IC50 = 6+/− 5 uM, n = 2, and NSC201631/61610 
(IC50 = 3.7 uM) (D) Two-Dimensional Chemical Structure of NSC201631, NSC61610, an NSC80734. Note: 
Synergistic competitive ELISA results obtained from four technical replicates of a single assay (n = 1). Standard 
deviation from mean is plotted with error bars.
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Figure 3. Virtual Docking of Identified Compounds. Autodock docking poses of compounds (A) NSC201631, 
(B) NSC80734, and (C) NSC61610. The docked conformation with the most favorable binding free energy 
and the most populated cluster was selected as the best result. Previously identified binding sites on hIL-18 
colored as site A (red), site B (orange), and site C (cyan) with the remaining surface of hIL-18 is colored in 
grey. Each individual compound is colored in yellow and shown using a stick figure. Zoomed inserts for each 
figure illustrate the predicted interactions of the compound with hIL-18 residues. For clarity, non-interacting 
residue sidechains have been omitted. Compound NSC201631 docked with a predicted potential of 8 hydrogen 
bonds and 25 hydrophobic interactions; NSC80734 docked with a predicted potential of 8 hydrogen bonds 
and 24 hydrophobic interactions; NSC61610 docked with a predicted potential of 10 hydrogen bonds and 26 
hydrophobic interactions.
Figure 4. IFN-γ Secretion Assay with selected inhibitors. Human IL-18 bioassay for the detection of secreted 
IFN-γ using increasing concentrations of hIL-18. (A) Inhibition curves obtained with a constant 1 uM inhibitor 
concentration and a cell concentration of 1 × 106 cells ml−1. (B) Synergistic inhibition curves obtained by 
adding a final concentration of 1 uM total inhibitor of both compounds, cell concentration was 1 × 106 cells 
ml−1.
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Lamarckian version of genetic algorithm where the conformational changes of molecules after in situ optimiza-
tion are used as subsequent poses for the offspring. Since there are no known structures of hIL-18 bound with 
inhibitors reported to date, we used a quasi “blind” docking method for defining the potential inhibitor binding 
locations on the surface of hIL-1846. In this approach, the entire hIL-18 interface that was involved in binding viral 
IL-18BP was used in docking to screen for potential inhibitors with lowest possible binding energy. The crystal 
structure of hIL-18 in complex with ectvIL-18BP (PDB entry 3F62) was used for our docking experiments26. Apo 
hIL-18 was generated by editing the pdb file and removing the ectvIL-18BP and all water molecules from the 
complex structure. Gasteiger charges were placed on the structure of apo hIL-18 using tools from the Autodock 
suite. The induced fit hIL-18 interface was used for docking purposes and the ligands were considered to be 
flexible. A grid box for ligand docking experiments was centered on the hIL-18 β-trefoil opening using 0.375 Å 
spacing with x, y, and z coordinates of 5.3, 10.2, 12.0 and a definition of 102 Å × 106 Å × 58 Å points, respectively. 
Additional experimental parameters used in Autodock include setting the population size to 300, the number of 
generations to 27,000 and the number of evaluations to 20,000,000. The number of docking runs was set to 50 
with a cutoff of 1 Å for the root mean square deviation (r.m.s.d.) for grouping of each docking run. As a starting 
point for virtual screening, the NCI Diversity Set II (http://dtp.cancer.gov) ligand library was used for docking 
experiments. The Diversity Set II contains approximately 1,500 compounds representing the greater than 250,000 
compounds of the NCI repository in a structural-data file (sdf) format47. For use in the Autodock program, the 
Diversity Set II sdf format was converted to three-dimensional coordinates at pH 7.4 in mol2 (Sybyl) format using 
the program Open Babel48. Gasteiger charges were generated for each compound using the scripts provided by 
the Autodock suite.
Protein Expression and Purification. The coding sequence for mature ectvIL-18BP (residues 21–126) 
was cloned into a modified pET28b expression vector as a fusion protein with an N-terminal 6x histidine tagged 
maltose binding protein (MBP) moiety. The coding sequence of tobacco etch virus (TEV) protease recognition 
site (ENLYFQG) was constructed in frame between MBP and ectvIL-18BP. This vector was transformed into E. 
coli BL21 (DE3) Rosetta-Gami 2 cells (Invitrogen) and grown in 2xYT media until A600 reached 0.8–1.0, at which 
time the temperature was lowered to 18° C. Protein expression was induced with a final concentration of 0.5 mM 
IPTG and allowed to continue for an additional 18 hrs. The MBP-ectvIL-18BP fusion protein was purified using 
the similar procedure as described49. Briefly, the fusion protein was purified first from the soluble cell lysates using 
a Ni-NTA affinity column. The MBP-ectvIL-18BP was further purified through size exclusion chromatography 
with a Superdex 200 column, concentrated to 4 mg ml−1, then flash frozen and stored at −80° C until usage50. 
Mature human IL-18 was cloned into a modified pET vector containing a C-terminal 6x His tag along with the 
coding sequence for a biotinylation sequence tag (GLNDIFEAQKIEWHE). The plasmids of IL-18 and biotin 
ligase (Cat # AVB101, www.avidity.com) were used for co-transformation into E. coli BL21 gold (DE3) cells. The 
biotinylated IL-18 was expressed and purified similarly as described above.
Competitive Enzyme-Linked Immunosorbant Assay (ELISA). We developed a chromogenic com-
petitive ELISA that displays reduced signal output when complex formation is perturbed between hIL-18 and 
ectvIL-18BP. Briefly, 50 ul of 1 ug ml−1 of MBP-ectvIL-18BP in 50 mM carbonate buffer, pH 9.6 was coated to 
Nunc Immulon Maxisorp plates (Thermo Scientific) at 37° C for 90 min. Plates were washed with a 1X PBS 
(50 mM Sodium Phosphate, 150 mM Sodium Chloride, pH 7.4) solution and then blocked for 3 hr at room tem-
perature with a 1% (w/v) casein solution (Sigma Aldrich) in 1X PBS solution. Plates were air dried at room 
temperature and then stored desiccated at 4° C until the assay was performed. The inhibitors were provided from 
Figure 5. Dose dependent inhibition of IFN-γ Production. Human IL-18 bioassay for the detection of secreted 
IFN-γ at a constant concentration of hIL-18. Inhibition curves obtained with increasing concentration of 
NSC80734 and a cell concentration of 1 × 106 cells ml−1.
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NCI and made to stocks at 10–20 mM concentration in 100% DMSO (Sigma Aldrich). The inhibitor stocks were 
subsequently diluted into 100% DMSO until an appropriate final inhibitor concentration was achieved. Purified 
biotinylated hIL-18 protein was diluted to 1 ug ml−1 then rapidly mixed with the inhibitor dilutions such that a 
final concentration of 5% (v/v) DMSO was achieved. 50 ul of the IL-18/inhibitor mix was added to each well and 
incubated at room temperature for 1 hr. Plates were washed 3 times with 1X PBST (PBS + 0.05% (v/v) Tween-
20) and subsequently incubated with 50 ul of a 1:1000 dilution of a 1 mg ml−1 Streptavidin-HRP (Horse Radish 
Peroxidase, Thermo Scientific) conjugate in 1X PBS for 1 hr at room temperature. Plates were washed again and 
developed with 50 ul of 3,3′,5,5′-tetramethylbenzidine (TMB) solution (Pierce) for 30 min at room temperature. 
The assay was stopped with 150 ul of 2 N sulphuric acid (Sigma Aldrich) and the absorbance at 450 nm was 
measured using a VersaMax microplate reader (Molecular Devices). Least squares fit analysis and IC50 were deter-
mined using GraphPad Prism 6 software (San Diego, CA, USA). Inhibition constant (Ki) were calculated with 
MBP-ectvIL-18BP, hIL-18 uM concentrations and a disassociation constant (Kd) of 0.2 nM using the web-based 
server BotDB51.
IFN-γ BioAssay. The hIL-18 bioassay was done similarly as previously described52. Briefly, KG-1 cells 
(0.25 ml at 1 × 106 cells ml−1) in RPMI medium containing 10% (v/v) Fetal bovine Serum were seeded in wells of 
a 96-well plate and stimulated with different concentrations of hIL-18. After stimulation at 37 °C for 24 hr, 100 ul 
of clarified supernatants was assayed for the secretion of human IFN-γ via ELISA (BD Biosciences), each hIL-18 
assay was done in duplicates (n = 2).
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